HEART TEST LABORATORIES-CW27 (HSCSW) Stock News
NASDAQ:HSCSW - Nasdaq - - Currency: USD
HSCSW Latest News, Press Relases and Analysis
RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results
On Thursday, Ascendiant analyst Edward Woo raised the price target on RenovoRx Inc. (NASDAQ:RNXT) to $11.50 from $11, while maintaining a Buy rating on the shares. This adjustment follows the company’s strong revenue growth reported in its Q1 2025 results. Woo indicated that the commercialization of RenovoCath and anticipated positive clinical data in Q3 will […]
HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with...
Mentions: HSCS
HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems
Mentions: HSCS
Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences’ Patent Portfolio and IP Value
Patent covers estimation of measures of heart function using an ECG, which are critical in the diagnosis and early detection of heart disease...
Mentions: HSCS
Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences’ Patent Portfolio and IP Value
Patent covers estimation of measures of heart function using an ECG, which are critical in the diagnosis and early detection of heart disease
Mentions: HSCS
HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone
Southlake, TX, May 29, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence...
Mentions: HSCS
HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone
Mentions: HSCS
HeartSciences’ CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025
Southlake, TX, May 20, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq:HSCS) (
Mentions: HSCS
HeartSciences’ CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025
Mentions: HSCS
HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson
Southlake, TX, May 08, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq:HSCS) (
Mentions: HSCS
HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson
Mentions: HSCS
HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board
Southlake, TX, May 07, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq:HSCS) (
Mentions: HSCS
HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board
Mentions: HSCS
HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program
Southlake, TX, May 01, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (
Mentions: HSCS
HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program
Mentions: HSCS
HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results
Southlake, TX, March 13, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (
Mentions: HSCS
HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results
Mentions: HSCS
HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications
Southlake, TX, March 10, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (
Mentions: HSCS
HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications
Mentions: HSCS
HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results
Southlake, TX, Dec. 16, 2024 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (
Mentions: HSCS
HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results
Mentions: HSCS
HeartSciences’ AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement
Southlake, TX, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the...
Mentions: HSCS
HeartSciences’ AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement
Mentions: HSCS
HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit
Southlake, TX, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (
Mentions: HSCS
HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit
Mentions: HSCS
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (
Mentions: HSCS
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
Mentions: HSCS
HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission
Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the...
Mentions: HSCS
HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission
Mentions: HSCS
HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
Southlake, TX, July 29, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (
Mentions: HSCS
HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
Mentions: HSCS
Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency
Southlake, TX, July 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the...
Mentions: HSCS
Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency
Mentions: HSCS
HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare
Southlake, TX, July 25, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the...
Mentions: HSCS
HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare
Mentions: HSCS
HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction
Further expands HeartSciences extensive patent portfolio...
Mentions: HSCS
HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction
Further expands HeartSciences extensive patent portfolio
Mentions: HSCS
HeartSciences Regains Compliance with Nasdaq Listing Requirements
Southlake, TX, June 04, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the...
Mentions: HSCS
HeartSciences Regains Compliance with Nasdaq Listing Requirements
Mentions: HSCS
HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio
Granted Indian Patent for its MyoVista® Wavelet Technology...
Mentions: HSCS